Current and Future Treatments for Classic Galactosemia

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Type I (classic) galactosemia is a hereditary disorder caused by galactose-1-phosphate uridylyltransferase (GALT) deficiency.
• Current dietary management effectively addresses neonatal issues but fails to prevent significant long-term complications.
• Recent advancements include animal models and GALT crystal structure resolution, offering insights into pathophysiology.

Purpose of the Study:

• To review novel therapeutic strategies for classic galactosemia.
• To highlight approaches targeting GALT activity restoration and downstream pathogenic factors.
• To provide an overview of the latest advancements in galactosemia treatment.

Main Methods:

• Review of current literature on classic galactosemia.
• Analysis of recent findings from animal models and structural biology of GALT.
• Synthesis of emerging therapeutic strategies focused on enzyme activity, disease cascade, and clinical management.

Main Results:

• Development of animal models partially mimicking galactosemia phenotypes.
• Resolution of GALT crystal structure providing biochemical insights.
• Exploration of novel therapies aiming to restore GALT function and mitigate disease progression.

Conclusions:

• Dietary restriction alone is insufficient for managing classic galactosemia long-term.
• Emerging therapies focus on restoring GALT activity and addressing complex pathogenic pathways.
• Further research is crucial to elucidate pathophysiology and develop effective treatments for burdensome complications.